PKN1 and cancer: In that context, it is worth noting that non-specific PKN1 inhibitors have already been validated for safe use in humans (Shibuya et al., 2005; Cohen et al., 2017) and the development of specific PKN1 inhibitors is a focus of cancer research (Ostrovskyi et al., 2016).